TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Jan 30, 2023 12:38 JST
Source:
Ocumension Therapeutics
Ocumension Therapeutics Appoints Mr. Tim RUAN and Mr. WANG Chong as Chief Financial Officer and Head of Investor Relations respectively
HONG KONG, Jan 30, 2023 - (ACN Newswire) - Ocumension Therapeutics (1477.HK) is pleased to announce that Mr. Tim RUAN and Mr. WANG Chong have been appointed as Chief Financial Officer and Head of Investor Relations respectively of the Group.
Mr. Tim RUAN has been newly appointed as Chief Financial Officer of Ocumension Therapeutics.
Mr. WANG Chong has been newly appointed as Head of Investor Relations of Ocumension Therapeutics.
Mr. Ruan will be responsible for the execution and management of all financial and investor relationship management of the Group. Mr. Ruan has more than 10 years of extensive experience in global capital markets, M&A, and financial management. Before joining the Group, Mr. Ruan served as an Executive Director of Investment Bank Division of Goldman Sachs. Prior to that, he worked as Vice President of Morgan Stanley and Associate of Nomura, respectively. He has also worked as an Associate in the capital markets and mergers and acquisitions department at a US law firm, Sullivan & Cromwell. Mr. Ruan holds a master's degree in Science (Biotechnology) from Hong Kong University of Science and Technology, and a bachelor's degree in Commerce, a bachelor degree of Laws from the University of New South Wales Australia.
Mr. Wang joined Ocumension Therapeutics in December 2022 as the Head of Investor Relations, and as Vice President of Ocumension (Hong Kong), he was mainly responsible for the execution of investor relationship management of the Group. Mr. Wang has accumulated over 15 years of experience in the securities industry. Before joining the Group, he served as the General Manager of Central China Finance Company Limited since 2018. He served as the Managing Director of Da Wan Asset Management Limitedfrom 2016 to 2018. Prior to that, he worked as a fund manager in Victory Securities Company Limited (stock code: 8540.HK). Mr. Wang holds a master's degree in Business Administration from Peking University's Guanghua School of Management.
Mr. Ye LIU, the Executive Director and CEO of Ocumension Therapeutics said, "Mr. Ruan and Mr. Wang both held key positions in a number of well-known enterprises, and they are veterans with professional experience that will assist in the formulation and implementation of the Company's development strategies, as well as enhancing the overall financial capability and our investor relationship management, thereby contributing to Ocumension Therapeutics's superior business performance. In addition, we believe that they will make valuable contributions to the Company, and create greater shareholders value with their substantial leadership and financial experience."
More information about Ocumension Therapeutics:
https://www.ocumension.com/
Source: Ocumension Therapeutics
Sectors: Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Ocumension Therapeutics: The Approval Received For Marketing OT-703 In Hong Kong, A New Option For Patients With Diabetic Macular Edema
December 20 2023 20:51 JST
Ocumension Therapeutics Announces 2023 Interim Results
August 24 2023 23:35 JST
Ocumension Therapeutics Announces 2022 Annual Results
March 30 2023 22:29 JST
Ocumension Therapeutics Announces Inclusion of Its Shares in the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect Programs
March 13 2023 18:30 JST
Ocumension Therapeutics Issues Positive Profit Alert for 2022 Annual Results
February 14 2023 10:57 JST
Ocumension Therapeutics Announces The Completion Of The Phase I Clinical Trial Of Its Class I New Drug For The Treatment Of Dry Eye -- OT-202
February 03 2023 10:01 JST
Ocumension Therapeutics Announces Its Patient Enrollment Completed In The Phase III Clinical Trail Of OT-101 In China
February 01 2023 10:00 JST
Ocumension Therapeutics (1477.HK) Announces 2020 Annual Results
March 20 2021 10:10 JST
More Press release >>
Latest Press Release
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
May 02, 2024 22:13 JST
Four-strong TOYOTA GAZOO Racing squad to push for more Portugal success
May 02, 2024 18:05 JST
Spectacular Spa awaits TOYOTA GAZOO Racing
May 02, 2024 17:46 JST
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore
May 02, 2024 11:00 JST
Sumitomo Metal Mining and Mitsubishi Corporation to Participate in Kalgoorlie Nickel Project - Goongarrie Hub
Apr 30, 2024 19:08 JST
SPARX Group Establishes Space Frontiers Second Fund
Apr 29, 2024 18:49 JST
MHI Establishes Local Subsidiary "Mitsubishi Heavy Industries Vietnam"
Apr 29, 2024 18:00 JST
POSCO Future M and Honda Reach Basic Agreement on Collaboration for Production of Cathode Materials for Automotive Batteries in Canada
Apr 29, 2024 14:25 JST
Honda Plans to Establish Comprehensive Electric Vehicle Value Chain in Ontario, Canada
Apr 29, 2024 14:16 JST
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
More Latest Release >>